

**CUSTOM PEPTIDES,
LOTS OF CHOICES.
ONLY ONE STANDARD
OF QUALITY.**


Choose the purity level that best suits your research, and your budget. Pick your quantity. Name your modification. But don't look for a choice in quality from Genosys — only the best is acceptable. So every Genosys peptide is verified by both HPLC and mass spectral analysis. 100% guaranteed, from \$25 per amino acid.

In North America, call
(800) 234-5362
GENOSYS

Genosys Biotechnologies, Inc.
1442 Lake Front Circle, Suite 185
The Woodlands, TX 77380-3600
Phone: (713) 363-3693
Fax: (713) 363-2212
E-mail: 73352.1236@compuserve.com

In Europe: Genosys Biotechnologies, Inc.
Cambridge, U.K.
Phone: +44 (0) 1223 425622
Fax: +44 (0) 1223 425966
E-mail: 100140.2401@compuserve.com

In Japan: Kurabo Industries Ltd.,
Biomedical Dept. (Osaka, Japan)
Phone: 0720-20-4504
Fax: 0720-21-9641



Circle No. 24 on Readers' Service Card

Don't Drown Your Data.

Water from conventional ultrapure systems can contain trace levels of ions, pyrogens, and organics that mask peaks in today's sensitive chromatography methods. Protect your data from being swamped with the Milli-Q® TOC Plus. It provides 18 megohm-cm, organic-free (<3 ppb TOC) water and comes with an integral TOC monitor — so you'll know the level of organics in the water prior to running your chromatogram. Keep your data above water with the Milli-Q TOC Plus. For more information, call 1-800-MILLIPORE, ext. 8316. In Europe, fax us at our European headquarters in Paris at 33-1-30.12.71.83.

© 1994 Millipore Corporation Millipore Lab Catalogue on Internet: Access URL: menu and type: http://www.millipore.com

MILLIPORE



Circle No. 46 on Readers' Service Card

and development of new ones along the entire continuum.

The article "Bumps on the vaccine road" by Jon Cohen (p. 1371) mentions the 31 August meeting in Geneva to address the integration of CVI into WHO's new vaccine program. This meeting has taken place, and the major governance issues have been resolved. WHO can now address the CVI goals confident of the strong organizational support of virtually all the principal agencies and donors in the field of vaccinology.

One has only to read the Perspectives in the 2 September issue (p. 1381) to realize that the CVI has not stumbled. It has already had an incalculably large impact on global thinking about vaccine development. With its consolidation with the Global Programme for Vaccines and Immunization, it will achieve its goals.

J. W. Lee

*Executive Secretary,
Children's Vaccine Initiative, and Director,
Global Programme for Vaccines and
Immunization, World Health Organization,
CH-1211, Geneva 27, Switzerland*

Career "Choice"

As a regular reader of Daniel E. Koshland Jr.'s editorials, I was surprised by the insensitivity of his reference to "choice of a career" in his 23 September editorial, "Careers in science" (p. 1787).

Unfortunately, too many in the public at large are employed, by economic necessity, in a job that they neither love nor are still interested in—they're stuck in their work, but they need the money! This probably holds true for many scientists as well, though likely a far smaller proportion than in the public as a whole.

Koshland's wording is insulting (although perhaps unintentionally) to those many adults who are not as fortunate as he and I to be employed doing something they "love." It also could be misunderstood by critics of science and academe as another example of experts—in this case, Koshland—being out of touch with "real life."

Paul J. Lavrakas

*Director, Survey Laboratory,
Northwestern University,
Evanston, IL 60208-4150, USA*

Response: I am well aware that many people take careers of necessity and that many scientists are trapped in boring jobs. That should not deter beginners from trying to find a career they expect to enjoy and all from recognizing that any job, even being editor of *Science*, involves some drudgery.

—**Daniel E. Koshland Jr.**